Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.

TAFRO-like syndrome associated with long-term CAR-T cell persistence after axicabtagene ciloleucel therapy.

Rapid recovery and functional resilience of bone marrow function post Bcell acute lymphoblastic leukemia.

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.

TAFRO-like syndrome associated with long-term CAR-T cell persistence after axicabtagene ciloleucel therapy.

Rapid recovery and functional resilience of bone marrow function post Bcell acute lymphoblastic leukemia.